Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of AZD2171 (Cediranib) With Modified FOLFOX6 in Patients With Advanced Biliary Cancers

NCT01229111 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01229111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01229111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of AZD2171 (Cediranib) With Modified FOLFOX6 in Patients With Advanced Biliary Cancers
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2010
Completion date
March 31, 2014
Enrollment
14 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

adult primary cholangiocellular carcinoma, advanced adult primary liver cancer, cholangiocarcinoma of the extrahepatic bile duct, cholangiocarcinoma of the gallbladder, localized unresectable adult primary liver cancer, periampullary adenocarcinoma, recurrent adult primary liver cancer, recurrent extrahepatic bile duct cancer, recurrent gallbladder cancer, unresectable extrahepatic bile duct cancer, unresectable gallbladder cancer